The report of Thrombosis Drugs Market by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Disease Type (Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis) Drug Class (Factor Xa Inhibitor, Heparin, P2Y12 Platelet Inhibitor) and Region (Asia Pacific, North America, Europe, Latin America, and Middle East Africa) is expected to reach US$ 41.34 Bn by 2026, at a CAGR of XX% during a forecast period.
Thrombosis is a biological process for the development of blood clot within artery or vein. The increased rate of thrombosis leads to formation of blood clots and blocks the flow of blood in an artery or a vein. Thrombosis drugs are used to prevent or treat the blood clot, which can cause different thrombotic events. It has been established that thrombosis is caused, due to certain cardiovascular disorders as a result of old age or obesity. There is an increasing burden of geriatric population, along with obesity, due to sedentary lifestyle across developed and emerging markets are driving the thrombosis drug market.
Factor Xa inhibitor segment is expected to grow at the highest XX% CAGR during the forecast period.
The factor Xa inhibitor segment led the market in 2018 and is expected to remain this trend during the forecast period, followed by the P2Y12 platelet inhibitor segment. Increasing preference for the usage of oral anticoagulant drugs with predictable dose release response is expected to impel the segment during the forecast period. The low molecular weight heparin drug class is expected to decrease market share during the forecast period owing to patent expiry.
The North America dominated the global thrombosis drugs market in 2018
North America is dominated the thrombosis drugs market followed by Europe and Asia Pacific. The availability of innovative anticoagulants, the presence of dominant market players, increased disease awareness, and rising healthcare expenditure make North America a dominant shareholder in the market. Asia Pacific is the fastest growing region owing to a rise in the prevalence of cardiovascular disease & other age-related chronic diseases, growing healthcare expenditure, and increasing access to healthcare services.
Key players operating the global thrombosis drugs market are Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Johnson & Johnson, Sanofi, Pfizer, Inc., Aspen Pharmacare Holdings, AstraZeneca plc, Daiichi Sankyo, Baxter International Inc., GlaxoSmithKline plc., Janssen Pharmaceuticals, Grifols Therapeutics Inc., Mylan Inc., Aurobindo Pharma, Biogen
Maximize Market Research, a global market research firm with a dedicated team of specialists and data has carried out extensive research about the global thrombosis drugs market. The report encompasses the market by different segments and region, providing an in-depth analysis of the overall industry ecosystem, useful for making an informed strategic decision by the key stakeholders in the industry. Importantly, the report delivers forecasts and share of the market, further giving an insight into the market dynamics, and future opportunities that might exist in the global thrombosis drugs market. The driving forces, as well as considerable restraints, have been explained in depth. in addition to this, competitive landscape describing the strategic growth of the competitors have been taken into consideration for enhancing market know-how of our clients and at the same time explain global thrombosis drugs market positioning of competitors.
Browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on “Thrombosis Drugs Market”
https://www.maximizemarketresearch.com/market-report/global-thrombosis-drugs-market/36310/
Contact:
MAXIMIZE MARKET RESEARCH PVT. LTD.
Omkar Heights,
ManikBaug, Vadgaon Bk,
Sinhagad Road, Pune – 411051, Maharashtra, India.
+91 9607195908